What is claimed is:

1. A compound having a Formula (I),



Formula I

a pharmaceutically acceptable salt, ester, amide or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug wherein:

X^0 and X^1 are each independently absent, O, S, NR^4, $-CH_2-CH_2-$, -CH=CH, or —C≡C—;

Ar^1 and Ar^2 are each independently absent or unsubstituted or substituted aryl or heteroaryl,

 is absent; or when present,  is a saturated or unsaturated hydrocarbon chain which is substituted or unsubstituted, wherein said chain has from 1 to 4 atoms so that  , Ar^1, X^1, $(CH_2)_r$ and Ar^2, together form a five to eight membered ring;

T is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 3 to 6 atoms wherein the carbon atom of position 1 is connected to the carbon atom of position 2 to form a five to eight member ring wherein the  is attached to a substitutionally available position of said ring;

X^2 is absent, O, S, or NR^4;

R^1, R^2, and $R^3$are independently hydrogen, lower alkyl, lower alkoxy, lower thioalkoxy, $-O(CH_2)_pCF_3$, halogen, nitro, cyano, -OH, -SH, $-CF_3$, $S(O)_pAlkyl$, $S(O)_pAryl$, $-(CH_2)_mOR^4$, or $-(CH_2)_mNR^5R^6$, COR^4, $-CONR^5R^6$, $-CO_2R^4$, or $-NR^5R^6$ or R^1 and R^2 are joined together to form a substituted or unsubstituted, saturated or unsaturated cyloalkyl or heterocycloalkyl ring;

R^4 is hydrogen, alkyl, alkenyl, alkynyl, acyl, SO_2Aryl, SO_2Alkyl or aryl;

R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, SO_2Alkyl aryl or SO_2Aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms;

R^7 and R^8 are independently H, lower alkyl, halo, or R^7 and R^8 taken together form a 3-6 membered hydrocarbon ring, optionally containing a heteroatom;

m is an integer from 0 to 5;

n is an integer from 0 to 5;

p is an integer from 0 to 2.

q is an integer from 0 to 10; and

r is an integer from 0 to 10.

2. A compound having a Formula II,



Formula (II)

a pharmaceutically acceptable salt, ester, amide or prodrug thereof or a pharmaceutically acceptable salt of the prodrug wherein:

X^3 is O, C=O, S, $CHOR^{11}$ where R^{11} is lower alkyl, aryl, acyl, -SO_2alkyl- or –SO_2aryl, absent or NR^4; R^1, R^2, and $R^3$are independently hydrogen, lower alkyl, lower alkoxy, lower thioalkoxy, -$O(CH_2)_pCF_3$, halogen, nitro, cyano, -OH, -SH, -CF_3, $S(O)_p$Alkyl, $S(O)_p$Aryl, -$(CH_2)_mOR^4$, or -$(CH_2)_mNR^5R^6$, COR^4, -$CONR^5R^6$, -CO_2R^4, or –NR^5R^6 or R^1 and R^2 are joined together to form a substituted or unsubstituted, saturated or unsaturated cyloalkyl or heterocycloalkyl ring;

R^4 is hydrogen, alkyl, alkenyl, alkynyl, acyl, SO_2Aryl, SO_2Alkyl or aryl;

R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, SO_2Alkyl aryl or SO_2Aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms;

R^7 and R^8 are independently H, lower alkyl, halo, or R^7 and R^8 taken together form a 3-6 membered hydrocarbon ring, optionally containing a heteroatom;

X^0 and X^1 are each independently absent, O, S, NR^4, $-CH_2-CH_2-$, -CH=CH, or —C≡C—; X^2 is absent, O, S, or NR^4;

Ar^1 and Ar^2 are each independently absent or unsubstituted or substituted aryl or heteroaryl,



is absent; or when present,



is a saturated or unsaturated hydrocarbon chain which is substituted or unsubstituted, wherein said chain has from 1 to 4 atoms so that



, Ar^1, X^1, $(CH_2)_r$ and Ar^2, together form a five to eight membered ring;

n is an integer from 0 to 5; q is an integer from 0 to 10; and r is an integer from 0 to 10.

3. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

X^0 is S or O;

X^1 is absent, O or S;

Ar^1 and Ar^2 are each independently absent, or unsubstituted or substituted aryl or heteroaryl;



is absent;

q is 1; and

r is 0 or 1.

4. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein: X^0 is S or O; X^1 is O or absent; and Ar^1 and Ar^2 are each independently unsubstituted or substituted aryl or heteroaryl.

5. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

T is $-CH_2CH_2CO-O-$, $-CH_2-CH_2-O-CO-$, $-CH_2-CH_2-CH_2-CH_2-$, -HC=CH-HC=CH-, -N=CH-HC=CH-, -HC=N-HC=CH-, -HC=CH-N=CH-, -HC=CH-HC=N-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-O-CH_2-$, $-CH_2-HC=CH-$, $-CH_2CH_2-NH-CH_2-$, -COCH=CH-O-, -O-CH=CH-CO-, -O-CH=CH-, -CH=CH-O-, $-O-CH_2-CH=CH-$, $-CH=CH-CH_2-O-$, $-CH_2-CH_2-CO-NR^4$, $-CH_2-CH_2-CO-CH_2-$, $-CH_2-CH_2-NR^4-CH_2-$, $-CH_2-NR^4-CH_2-CH_2-$, $-CH=CH-NR^4-$, $-NR^4-CH=CH-$, $-CH=CH-CH_2-$, $-CH_2-CH_2-NR^4-$, $-NR^4-CH_2-CH_2-$, $-O-CH_2-CH_2-$, $-O-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-O-$, $-CH_2-CH_2-CH_2-O-$, $-O-CH(CH_3)-CH_2-CH_2-$, $-CH_2-CH_2-$ $CH(CH_3)-O-$, $-CH_2-CH_2-CH_2-NR^4-$, $-NR^4-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CO-NR^4-$, $-NR^4-CO-CH_2-CH_2-$, -O- NR^4-CO-, -CO- NR^4-O-, $-O-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-O-$, $-CH_2-CH_2-NR^4-CO-$, $-CH_2-CH_2-CH_2-CO-$, $-CO-CH_2-CH_2-CH_2-$, $-NR^4-CO-CH_2-CH_2-$, $-CO-NR^4-CH_2-CH_2-$, $-CH_2-CH_2-CO-$, $-CH_2-CO-CH_2-$,–CO-CH_2-CH_2-,-S-C=C-,. –C=C-S-, -S-C-C, -C-C-S-, -S-C-C-C-, -C-C-C-S-, -C=C-C-S-, -C-C=C-S-, -S-C=C-C-, or –S-C-C=C-.

6. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein :

X^0 is S;

X^1 is absent;

Ar^1 is substituted phenyl;

Ar^2 is phenyl;



is absent;

q is 1; and

r is 0 or 1.

7. A compound of claim 3, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

T is substituted with 1 or more substituents selected from the group consisting of lower alkyl, lower alkoxy, lower thioalkoxy, $-O(CH_2)_{0-2}CF_3$, halogen, nitro, cyano, =O, =S, -OH, -SH, $-CF_3$, $-CO_2H$, $-CO_2C_1-C_6$ alkyl, $-NH_2$, $-NHC_1-C_6$ alkyl, –CONR'R", or $-N(C_1-C_6alkyl)_2$; and

R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring.

8. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein q is 1.

9. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein Ar^1 is substituted or unsubstituted phenyl.

10. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein Ar^2 is 4-trifluoromethylphenyl.

11. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein 

is absent.

12. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein 

is $(CH_2)_t$ and t is an integer from 1 to 4.

13. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein



is substituted with at least one substituent selected from the group consisting of lower alkyl, lower alkoxy, lower thioalkoxy, $-O(CH_2)_{0-2}CF_3$, halogen, nitro, cyano, =O, =S, -OH, -SH, $-CF_3$, $-OCF_3$, $-CO_2H$, $-CO_2C_1$-C_6 alkyl, $-NH_2$, $-NHC_1$-C_6 alkyl, –CONR'R", or $-N(C_1$-C_6alkyl$)_2$ where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring.

14. A pharmaceutical composition comprising a compound of Claim1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; and a pharmaceutically acceptable carrier, diluent, or vehicle.

15. A method of treating, preventing or controlling non-insulin dependent diabetes mellitus in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

16. A method of treating, preventing or controlling obesity in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

17. A method of treating, preventing or controlling hyperglycemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

18. A method of treating, preventing or controlling hyperlipidemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

19. A method of treating, preventing or controlling hypercholesteremia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

20. A method of treating, preventing or controlling atherosclerosis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

21. A method of treating, preventing or controlling hypertriglyceridemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or

prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

22. A method of treating, preventing or controlling hyperinsulinemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

23. A method of treating a patient exhibiting glucose disorders associated with circulating glucocorticoids, growth hormone, catecholamines, glucagon, or parathyroid hormone, comprising administering to the patient a therapeutically effective amount of a compound of Claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug; or a compound of Claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug.

24. A compound of claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein X^3 is NR^4 or C=O.

25. A compound of claim 2, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein Ar^2 is chloro-phenyl, dichloro-phenyl-, trichlorophenyl, fluoro-phenyl-, difluorophenyl, trifluorophenyl, trifluoromethyl-phenyl, or fluoro-trifluoromethyl-phenyl-; and wherein Ar^1 is absent.

26. A compound of claim 1 having Formula 1a, Formula 1b, Formula 1c, Formula 1d, Formula 1e, Formula 1f, Formula 1g, or Formula 1h,



1a



1b



1c



1d



1e



1f



1g



1h

or the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug wherein:

X^0 is O or S;

X^2 is absent, O, S, or NR^4;

R^1, R^2, and $R^3$are independently hydrogen, lower alkyl, lower alkoxy, lower thioalkoxy, $-O(CH_2)_pCF_3$, halogen, nitro, cyano, -OH, -SH, $-CF_3$, $S(O)_pAlkyl$, $S(O)_pAryl$, $-(CH_2)_mOR^4$, or $-(CH_2)_mNR^5R^6$, COR^4, $-CO_2H$, $-CO_2R^4$, or $-NR^5R^6$ or R^1 and R^2 are joined together to form a substituted or unsubstituted, saturated or unsaturated cyloalkyl or heterocycloalkyl ring;

R^4 is hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, SO_2Alkyl or, SO_2Aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms;

m is an integer from 0 to 5;

n is an integer from 0 to 5;

p is an integer from 0 to 2,

Z^1, Z^2, Z^3, and Z^4 are independently O, S, CR^5R^6, NR^{11}, or N;

R^{11} is lower alkyl, acyl, aralkyl, $-SO_2$alkyl, or $-SO_2Ar$, and wherein

Z^1, Z^2, Z^3, and Z^4 are bonded to a sufficient number of hydrogen atoms or substituents to complete the valency of each atom with the proviso that Z^1, Z^2, Z^3, and Z^4 are not all heteroatoms and that not more than two adjacent atoms in Z^1, Z^2, Z^3, and Z^4 are heteroatoms and that in Formulae 1b, 1c, 1d, 1f, and 1g, Z^1, Z^2, Z^3, and Z^4 are not all carbon atoms; and X^1, Ar^1, Ar^2, 

, r and q are as defined in claim 1.

27. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

R^1, R^2, and R^3 are independently hydrogen, alkyl, or alkoxy.

28. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

R^1 and R^3 are hydrogen; and

R^2 is alkyl or alkoxy.

29. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

$R^1$and R^3 are hydrogen; and

R^2 is alkoxy.

30. A compound of claim 1, the pharmaceutically acceptable salt, ester, amide or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug, wherein:

R^1 and R^3 are independently hydrogen, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl; and

R^2 is methyoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy.

31. A compound selected from the group consisting of: [6-(4'-Trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-chroman-2-yl]-acetic acid; {6-[4-(5-Trifluoromethyl-pyridin-2-yl)-benzylsulfanyl]-chroman-2-yl}-acetic acid; {6-[4-(2,5-Dichloro-benzyloxy)-benxylsulfanyl}-chroman-2-yl}-acetic acid; {6-[4-(4-Trifluoromethyl-benzyloxy)-benzylsulfanyl]-chroman-2-yl}-acetic acid; {6-[5-(4-Trifluoromethyl-phenyl)-isoxazol-3-ylmethylsulfany]-chroman-2-yl}-acetic acid; {6-[3-(4-Trifluoromethyl-benzyloxy)-benzylsulfanyl]-chroman-2yl}-acetic acid; {6-[2-(4-Trifluoromethyl-phenyl)-thiazol-4-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid; {6-[4-(4-Trifluoromethyl-benzyloxy)-benzyloxy]-benzo[b]thiophen-3-yl}-acetic acid; {6-[2-(4-Trifluoromethyl-benzyloxy)-benzyloxy]-benzo[b]thiophen-3-yl}-acetic acid; and pharmaceutically acceptable salts thereof.

32. A compound having a formula (IA),



Formula (IA)

a pharmaceutically acceptable salt, ester, amide, or prodrug thereof ,or a pharmaceutically acceptable salt of the prodrug wherein:

Z=S, O or NR^4, Ar^1 and Ar^2 are each independently absent or unsubstituted or substituted aryl or heteroaryl,



is absent; or when present,

is a saturated or unsaturated hydrocarbon chain which is substituted or unsubstituted, wherein said chain has from 1 to 4 atoms so



that , Ar^1, X^1, $(CH_2)_r$ and Ar^2, together form a five to eight membered ring;

X^0 and X^1 are each independently absent, O, S, NR^4, $-CH_2-CH_2-$, -CH=CH, or —C≡C—; X^2 is absent, O, S, or NR^4; R^1 is independently hydrogen, lower alkyl, lower alkoxy, lower thioalkoxy, $-O(CH_2)_pCF_3$, halogen, nitro, cyano, -OH, -SH, $-CF_3$, $S(O)_pAlkyl$, $S(O)_pAryl$, $-(CH_2)_mOR^4$, $-(CH_2)_mNR^5R^6$, COR^4, $-CONR^5R^6$, $-CO_2R^4$, or $-NR^5R^6$;

R^4 is hydrogen, alkyl, alkenyl, alkynyl, acyl, SO_2Aryl, SO_2Alkyl or aryl;

R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, SO_2Alkyl aryl or SO_2Aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms;

R^7 and R^8 are independently H, lower alkyl, halo, or R^7 and R^8 taken together form a 3-6 membered hydrocarbon ring, optionally containing a heteroatom;

n is an integer from 0 to 5;

q is an integer from 0 to 10; and

r is an integer from 0 to 10.

33. A compound selected from the group consisting of: {6-[4-(4-Trifluoromethyl-benzyloxy)-benzyloxy]-benzo[b]thiophen 3-yl}-acetic acid; {6-[5-(4-Trifluoromethyl-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid; {6-[3-(4-Trifluoromethyl-benzyloxy)-benzyloxy]-benzo[b]thiphen-3-yl}-acetic acid; {6-[2-(4-Trifluoromethyl-phenyl)-thiazol-4-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid; {6-

[5-(4-Chloro-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid; and pharmaceutically acceptable salts thereof.

34. A compound of claim 32, the pharmaceutically acceptable amide ester or prodrug thereof, or the pharmaceutically acceptable salt of the prodrug wherein:

X^o is oxygen;

X^1 is absent or O;

Ar^1 is a substituted or unsubstituted aryl or heteroaryl;

Ar^2 is a substituted phenyl;



is absent;

X^2 is absent

n is an integer from 0 to 5

q is an integer from 0 to 3; and

r is an integer from 0 to 3.

35. A compound having a Formula III,



Formula (III)

a pharmaceutically salt, ester amide or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug wherein:

Ar^1 and Ar^2 are each independently absent or unsubstituted or substituted aryl or heteroaryl,

 is absent; or when present,  is a saturated or unsaturated hydrocarbon chain which is substituted or unsubstituted, wherein said chain has from 1 to 4 atoms so

 that , Ar^1, X^1, $(CH_2)_r$ and Ar^2, together form a five to eight membered ring;

X^0 and X^1 are each independently absent, O, S, NR^4, $-CH_2-CH_2-$, -CH=CH, or —C≡C—; X^2 is absent, O, S, or NR^4;

R^4 is hydrogen alkyl, alkenyl, alkynyl, acyl, SO_2Aryl, SO_2Alkyl or aryl;

R^7 and R^8 are independently H, lower alkyl, halo, or R^7 and R^8 taken together form a 3-6 membered hydrocarbon ring, optionally containing a heteroatom;

n is an integer from 0 to 5;

q is an integer from 0 to 10; and

r is an integer from 0 to 10.

36. A compound selected from the group consisting of: 3-{1-[3-(4-Trifluoromethyl-benzyloxy)-benzyl]-1H-indol-3yl}-propionic acid; 3-{1-[4-(4-Trifluoromethyl-benzyloxy)-benzyl]-1H-indol-3-yl}-propionic acid; 3-[1-(4'-Trifluoromethyl-biphenyl-4-ylmethyl)-1H-indol-3-yl]-propionic acid; {1-[3-(4-Trifluoromethyl-benzyloxy)-benzyl]-1H-indol-3-yl}-acetic acid, and pharmaceutically acceptable salts thereof.

37. A compound having a Formula IV,



Formula (IV)

a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug wherein:

Ar^1 and Ar^2 are each independently absent or unsubstituted or substituted aryl or heteroaryl,

 is absent; or when present,  is a saturated or unsaturated hydrocarbon chain which is substituted or unsubstituted, wherein said chain has from 1 to 4 atoms so that  , Ar^1, X^1, $(CH_2)_r$ and Ar^2, together form a five to eight membered ring;

X^0 and X^1 are each independently absent, O, S, NR^4, $-CH_2-CH_2-$, -CH=CH, or —C≡C—; X^2 is absent, O, S, or NR^4;

R^4 is hydrogen alkyl, alkenyl, alkynyl, acyl, SO_2Aryl, SO_2Alkyl or aryl;

R^7 and R^8 are independently H, lower alkyl, halo, or R^7 and R^8 taken together form a 3-6 membered hydrocarbon ring, optionally containing a heteroatom;

n is an integer from 0 to 5;

q is an integer from 0 to 10; and

r is an integer from 0 to 10.

38. A compound selected from the group consisting of: [1-(4'-Trifluoromethyl-biphenyl-4-ylmethyl)-1H-indol-5-yloxyl]-acetc acid, [1-(4'-Trifluoromethyl-biphenyl-4-ylmethyl)-1H-indol-4-yloxy]-acetic acid; and pharmaceutically acceptable salts thereof.

39. A compound selected from the group consisting of: [6-(4'-Trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-chroman-2-yl]-acetic acid; {6-[5-(4-Trifluoromethyl-phenyl)-isoxazol-3-ylmethylsulfany]-chroman-2-yl}-acetic acid; {6-[2-(4-Trifluoromethyl-phenyl)-thiazol-4-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid; and pharmaceutically acceptable salts thereof.

40. A compound of claim 35, a pharmaceutically acceptable salt, amide, ester or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug wherein:

X^o is absent

X^1 is absent or O;

Ar^1 is a substituted or unsubstituted phenyl;

Ar^2 is 4-trifluoromethyl phenyl;



is absent;

X^2 is absent, 0, or S;

n is an integer from 0 to 5;

q is an integer from 0 to 3; and

r is an integer from 0 to 3.

41. A compound of claim 37, a pharmaceutically acceptable salt, amide, ester, prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, wherein:

X^0 and X^1 are absent;

Ar^1 is a substituted or unsubstituted phenyl;

Ar^2 is 4-trifluoromethylphenyl;



is absent;

X^2 is absent, 0 or S;

n is an integer from 0 to 5;

q is an integer from 0 to 3; and

r is an integer from 0 to 3.

42. A compound of claim 34, a pharmaceutically acceptable salt, ester, amide or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, wherein Ar^2 is trifluoromethyl-phenyl.

43. A method of making a compound of claim 1 having the Formula (I):



Formula (I)

wherein X^o, X^1, Ar^1, Ar^2, , T, X^2, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, m, n, p, q and r are as defined in claim 1.

comprising:

reacting a compound of Formula A,



Formula (A)

wherein R^{10} is a lower alkyl, with a compound of Formula B,



Formula (B)

wherein L is an appropriate leaving group and X^3 is absent, to form a compound having a Formula C,



Formula (C)

and subsequently saponifying the compound having a Formula C to form the compound having the Formula I.

44. A compound having a Formula IIA,



Formula (IIA)

a pharmaceutically acceptable salt, amide ester or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug wherein:

X^1 and X^3 are each independently O, C=O, S, $CHOR^{11}$, absent or NR^4; R^1, R^2, R^3 and R^9 are independently hydrogen, lower alkyl, lower alkoxy, lower thioalkoxy, $-O(CH_2)pCF_3$, halogen, nitro, cyano, -OH, -SH, $-CF_3$, $S(O)_pAlkyl$, $S(O)_pAryl$, $-(CH_2)_mOR^4$, $-(CH_2)_mNR^5R^6$, $-COR^4$, $-CO_2H$, $-CO_2R^4$, or $-NR^5R^6$, or R^1 and R^2 are joined together to form a substituted or unsubstituted, saturated or unsaturated cycloalkyl or heterocycloalkyl ring; R^{11} is lower alkyl, aryl, acyl, $-SO_2Alkyl$, SO_2Aryl, absent or NR^4; X^1 and X^0 are each independently absent, O, S, NR^4, $-CH_2-CH_2-$, -CH=CH, or —C≡C—; Ar^1 and Ar^2 are each independently absent or unsubstituted or substituted aryl or heteroaryl,

X^2 is absent, O, S, or NR^4;

R^4 is hydrogen, alkyl, alkenyl, alkynyl, acyl, SO_2Aryl, SO_2Alkyl or aryl;

R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, SO_2Alkyl aryl or SO_2Aryl, or joined together to form a 4 to 7 member ring having 0 to 3 heteroatoms;

R^7 and R^8 are independently H, lower alkyl, halo, or R^7 and R^8 taken together form a 3-6 membered hydrocarbon ring, optionally containing a heteroatom;

m is an integer from 0 to 5;

n is an integer from 0 to 5;

p is an integer from 0 to 2.

q is an integer from 0 to 10; and

r is an integer from 0 to 10.

45. A compound of claim 32 having the Formula IIB,



Formula (IIB)

a pharmaceutically acceptable salt, ester, or amide thereof, or a pharmaceutically acceptable salt of the prodrug wherein:

Z is NR^4, S, or O; and R^1, R^4, X^0, X^1, Ar^1, Ar^2, , q and r are as defined in claim 32.

46. A method of making a compound of claim 45 having the Formula IIB



Formula (IIB)



wherein Z, R^1, R^4, X^0, X^1, Ar^1, Ar^2, , q and r are as defined in claim 45, comprising reacting a compound of Formula H wherein R^{10} is a lower alkyl,



Formula (H)

with a compound of Formula B:



L= leaving group Formula (B)

wherein L is an appropriate leaving group, to form a compound of Formula J:



Formula (J)

and subsequently saponifying the compound of Formula J to form the compound IIB.

47. A compound selected from the group consisting of :

{6-[5-(4-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(3-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(4-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(3-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzo[b]thiophen-3-yl}-acetic acid;

{5-Methoxy-6-[5-(4-methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid;

{5-Methoxy-6-[5-(3-methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-5-methoxy-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-5-methoxy-benzo[b]thiophen-3-yl}-acetic acid;

{6-[5-(4-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid;

{6-[5-(3-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid;

{6-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid;

{6-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid;

{6-[5-(4-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzofuran-3-yl}-acetic acid;

{6-[5-(3-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzofuran-3-yl}-acetic acid;

{6-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzofuran-3-yl}-acetic acid;

{6-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-4-methyl-benzofuran-3-yl}-acetic acid;

{5-Methoxy-6-[5-(4-methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid;

{5-Methoxy-6-[5-(3-methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid;

{6-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-5-methoxy-benzofuran-3-yl}-acetic acid;

{6-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-5-methoxy-benzofuran-3-yl}-acetic acid;

{7-[5-(4-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-indan-4-yloxy}-acetic acid;

{7-[5-(3-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-indan-4-yloxy}-acetic acid;

{7-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-indan-4-yloxy}-acetic acid;

{7-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-indan-4-yloxy}-acetic acid;

{4-[5-(4-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-2-methyl-phenoxy}-acetic acid;

{4-[5-(3-Methoxymethyl-phenyl)-isoxazol-3-ylmethoxy]-2-methyl-phenoxy}-acetic acid;

{4-[5-(4-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-2-methyl-phenoxy}-acetic acid;

{4-[5-(3-Methanesulfonyloxy-phenyl)-isoxazol-3-ylmethoxy]-2-methyl-phenoxy}-acetic acid; and pharmaceutically acceptable salts thereof.